Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment

Luye Pharma in-licensed greater China rights to PharmaMar's lurbinectedin (Zepsyre®) as a treatment for small cell lung cancer (SCLC). Luye will make an up-front payment of $5 million followed by additional regulatory and sales milestones, as well as double-digit royalties. If lurbinectedin is approved for other indications, Luye will make additional payments. Lurbinectedin is an inhibitor of RNA polymerase II, which is essential for the transcription process. PharmaMar, a Madrid biopharma, is developing the drug in tumors with transcription addiction. More details.... Stock Symbols: (HK: 2186) (MSE: PHM) Share this with colleagues: // //